Change Visitor Type



Oxford Capital exited its investment in Sirigen in August 2012. Sirigen was acquired by Becton, Dickinson and Company, a leading global medical technology company for $65 million.

Sirigen commercialised a novel application of conducting polymers in the medical diagnostics market. Sirigen’s technology adds “high sensitivity fluorescence” (HSF) to diagnostic techniques, as well as simplifying sample processing and instrumentation requirements. Generating sufficient signal from diagnostic tests, in order to be sure of an accurate diagnosis, is a key challenge for the diagnostic industry. By incorporating the light-harnessing power of the Sirigen polymers, the signal from the diagnostic is greatly increased.

  • UltraSoC strengthens management team with appointment of CFO

    Read more
  • UltraSoC embedded analytics selected to support Wave Computing’s TritonAI 64 IP platform

    Read more

  • News and Views

    The lastest industry news and views
    from our team at Oxford Capital.

    see more
  • The changing face of UK VC: Esther Delignat-Lavaud Rodriguez, investor at Oxford Capital

    Read more
  • Latent Logic moves into new office in Oxford

    Read more
  • Oxford Capital has led a £6.5m series-A funding round for UK-headquartered courier service Weengs.

    Read more
  • Cycle-accurate trace boosts performance optimization capabilities of UltraSoC embedded analytics infrastructure

    Read more